Delivery Order 75N95019D00037-75N95020F00192
Award Date
9/24/20
Potential Completion Date
9/23/22
Potential Value
Not listed
Federal Agency
National Institute on Drug Abuse
Awardee
Xenobiotic Laboratories Inc.
Ultimate Awardee
Not listed
NAICS Category
541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Plainsboro Township, NJ 08536, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Service Contract Act
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
Xenobiotic Laboratories Inc. was awarded a firm fixed price delivery order against the Analytical Services Center for Medications Development Program for analytical services. The delivery order, valued at $0.00 with a period of performance from September 25, 2019 through May 23, 2022, was issued by the National Institute on Drug Abuse, part of the Department of Health and Human Services National Institutes of Health. Under the delivery order, Xenobiotic Laboratories Inc.'s Biotesting Division...
Xenobiotic Laboratories Inc. was awarded a firm fixed price delivery order against the Analytical Services Center for Medications Development Program for analytical services. The one year, $0.00 potential value task order was awarded by the National Institute on Drug Abuse within the Department of Health and Human Services to support the Center's work developing medications. Performance will take place in Plainsboro Township, New Jersey by Xenobiotic's Biotesting Division. No set aside...
Xenobiotic Laboratories Inc. Biotesting Division was awarded a $71,740 firm fixed price purchase order by the Department of Health and Human Services National Institutes of Health National Center for Advancing Translational Sciences to assess the cytochrome P450 (CYP450) enzyme induction potential of two test articles. Performance will take place in Plainsboro Township, New Jersey from August 2023 through March 2024. The award is in response to a solicitation requesting evaluation of the test...
This is a firm fixed price federal contract awarded by the National Institute on Drug Abuse (NIDA), a part of the National Institutes of Health (NIH), to Xenotech LLC, doing business as Sekisui-Xenotech. The purpose of the contract is to provide in vitro metabolism and metabolite quantification services over a 5-year period of performance. The total ceiling value of the contract is $1,463,840.30. Xenotech is a small disadvantaged business that specializes in providing biomedical research...
This is a firm-fixed-price purchase order awarded by the National Institute on Drug Abuse (NIDA), a civilian agency under the Department of Health and Human Services, to Cyprotex US LLC, a foreign-owned for-profit contract research organization. The $109,392.00 contract is for compound testing services, including plasma protein binding studies, PXR and AhR activation studies, and CYP inhibition assays on various small molecule compounds. This work supports NIDA's mission to seek fundamental...
This is a purchase order awarded by the U.S. Department of Health and Human Services, National Institutes of Health, National Institute on Drug Abuse (NIDA) to Xenotech LLC, a small disadvantaged business doing business as Sekisui-Xenotech. The $41,496 firm fixed price contract is for the delivery of 300 vials (1mL each) of "Mixed Gender Human Liver Microsomes" to support the National Center for Advancing Translational Sciences (NCATS) Tox21 program's research on drug metabolism and...
This is a firm fixed-price delivery order issued by the Department of Health and Human Services' National Institutes of Health National Institute on Drug Abuse (NIDA) to Eurofins Panlabs, Inc., a foreign-owned for-profit contract research organization. The $359,131 order is for a 1-year period of performance from September 30, 2020 to September 29, 2021 under the NIDA N01DA-18-8937 contract vehicle. The work involves receptor binding and predictive toxicology services to support NIDA's drug...
The Department of Health and Human Services National Institutes of Health National Institute on Drug Abuse awarded a $113,135 firm fixed price delivery order to National Medical Services, Inc., doing business as NMS Labs, against its indefinite-delivery/indefinite-quantity contract number 75N95020D00002. This task order, number 2 under the IDIQ, is for $100,000 in NIMH tissue toxicology testing as described in Attachment 1 and NMS Labs' proposal dated December 20, 2019. The work will be...
This award is a $111,339.20 firm fixed-price delivery order under a larger Indefinite Delivery/Indefinite Quantity (IDIQ) contract with the National Institute on Drug Abuse (NIDA), a civilian agency under the Department of Health and Human Services. The award is for neurobiobank tissue toxicology testing services provided by National Medical Services, Inc. (doing business as NMS Labs), a for-profit organization specializing in clinical and forensic laboratory services. This delivery order will...
This federal contract award was made by the National Institute on Drug Abuse (NIDA), a civilian agency under the National Institutes of Health (NIH), to Pharmaron, Inc. The $101,372.00 firm fixed-price delivery order contract is part of the NIH Bioanalysis Testing Services 2015-2020 indefinite-delivery, indefinite-quantity (IDIQ) contract vehicle. Under this award, Pharmaron will provide a range of preclinical research services to support NIDA's drug discovery and development initiatives,...